Your browser doesn't support javascript.
loading
Accelerating multiplexed profiling of protein-ligand interactions: High-throughput plate-based reactive cysteine profiling with minimal input.
Yang, Ka; Whitehouse, Rebecca L; Dawson, Shane L; Zhang, Lu; Martin, Jeffrey G; Johnson, Douglas S; Paulo, Joao A; Gygi, Steven P; Yu, Qing.
Afiliação
  • Yang K; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
  • Whitehouse RL; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
  • Dawson SL; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
  • Zhang L; Biogen, Cambridge, MA 02142, USA.
  • Martin JG; Biogen, Cambridge, MA 02142, USA.
  • Johnson DS; Biogen, Cambridge, MA 02142, USA.
  • Paulo JA; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
  • Gygi SP; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: steven_gygi@hms.harvard.edu.
  • Yu Q; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: qing_yu2@hms.harvard.edu.
Cell Chem Biol ; 31(3): 565-576.e4, 2024 Mar 21.
Article em En | MEDLINE | ID: mdl-38118439
ABSTRACT
Chemoproteomics has made significant progress in investigating small-molecule-protein interactions. However, the proteome-wide profiling of cysteine ligandability remains challenging to adapt for high-throughput applications, primarily due to a lack of platforms capable of achieving the desired depth using low input in 96- or 384-well plates. Here, we introduce a revamped, plate-based platform which enables routine interrogation of either ∼18,000 or ∼24,000 reactive cysteines based on starting amounts of 10 or 20 µg, respectively. This represents a 5-10X reduction in input and 2-3X improved coverage. We applied the platform to screen 192 electrophiles in the native HEK293T proteome, mapping the ligandability of 38,450 reactive cysteines from 8,274 human proteins. We further applied the platform to characterize new cellular targets of established drugs, uncovering that ARS-1620, a KRASG12C inhibitor, binds to and inhibits an off-target adenosine kinase ADK. The platform represents a major step forward to high-throughput proteome-wide evaluation of reactive cysteines.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteoma / Cisteína Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteoma / Cisteína Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article